Concord Drugs Limited (CONCORD.BO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-217.1%

-₹79.20

vs ₹67.62 price

Levered DCF

-₹43.41

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

—

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	83.11×	93.56×	78.38×	25.9×	15.93×	7.75×	34.47×	40.38×
P/B	1.8×	0.92×	1.09×	0.81×	0.89×	0.95×	0.49×	0.71×
P/S	1.11×	0.7×	0.82×	0.49×	0.43×	0.49×	0.22×	0.34×
EV / EBITDA	22.15×	11.7×	13.43×	9.27×	7.34×	5.49×	6.24×	7.03×
Gross margin	14.1%	22.1%	26.0%	21.2%	28.5%	16.1%	16.8%	17.0%
Operating margin	4.0%	6.0%	5.6%	5.8%	15.5%	3.9%	9.9%	5.2%
Net margin	1.3%	0.7%	1.1%	1.9%	2.7%	6.4%	0.6%	0.8%
Current ratio	2.53×	1.56×	2.09×	2.01×	1.77×	2.22×	1.47×	1.24×
Debt / equity	0.28×	0.5×	0.52×	0.54×	0.58×	0.48×	0.41×	0.42×
Interest coverage	1.86×	1.33×	1.36×	1.76×	5.46×	1.5×	3.53×	1.58×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	2.2%	1.0%	1.4%	3.1%	5.6%	12.3%	1.4%	1.8%
Return on invested capital	3.5%	2.4%	3.5%	4.6%	13.7%	3.6%	10.3%	6.4%
Return on assets	1.4%	0.5%	0.8%	1.7%	2.8%	6.6%	0.6%	0.5%
Free cash flow yield	-9.1%	4.4%	-0.6%	3.2%	-6.6%	-14.5%	14.3%	5.2%
Earnings yield	1.2%	1.1%	1.3%	3.9%	6.3%	12.9%	2.9%	2.5%
Enterprise value	₹1B	₹485.3M	₹544M	₹424.6M	₹417.5M	₹383.4M	₹210.1M	₹261.8M
Net debt / EBITDA	2.93×	4.11×	4.29×	3.69×	2.88×	1.85×	2.84×	2.6×
Cash conversion cycle (days)	213	293	375	242	231	221	212	146